CSPC Pharmaceutical Group (HKG:1093) expects a 26% year-over-year decline in attributable profit for the year 2024 from around 5.87 billion yuan a year prior, a Tuesday filing with the Hong Kong bourse said.
The pharmaceutical firm attributed the lower anticipated profit mainly to a decrease in revenue of the finished drugs business.
Shares of the company were down nearly 4% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。